Potent LpxC Inhibitors with In Vitro Activity against Multidrug-Resistant Pseudomonas aeruginosa

Authors:

Abstract
New drugs with novel mechanisms of resistance are desperately needed to address both community and nosocomial infections due to Gram-negative bacteria. One such potential target is LpxC, an essential enzyme that catalyzes the first committed step of lipid A biosynthesis. Achaogen conducted an extensive research campaign to discover novel LpxC inhibitors with activity against Pseudomonas aeruginosa .
Funding Information
  • CARB-X (IDSEP 160030-01-02)
  • The Military Medical Research and Development Program, Defense Health Program, Department of Defense (W81XWH122000040)
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (HHSN272201500009C)
  • DOD | Defense Threat Reduction Agency (HDTRA107C0079)
  • Wellcome Trust (IDSEP 160030-01-02)

This publication has 20 references indexed in Scilit: